Loading company…
German biopharmaceutical company developing and manufacturing biologics, including viral vectors and mRNA therapies.
Vibalogics GmbH provides biologics drug development and manufacturing services, focusing on advanced therapies such as mRNA, lipid nanoparticles, and viral vectors for pharmaceutical and biotech clients. In 2022 it reported revenue of USD 9.17 mn and EBITDA of USD 2.05 mn. Founded in 2002 and headquartered in Germany, the company was fully acquired by Recipharm AB from Ampersand Capital Partners in February 2022, and Tom Hochuli is CEO.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in